{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:43:46Z","timestamp":1777923826865,"version":"3.51.4"},"reference-count":23,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T00:00:00Z","timestamp":1543536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T00:00:00Z","timestamp":1543536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Nucleic Acid Therapeutics"],"published-print":{"date-parts":[[2018,12,1]]},"abstract":"<jats:p>\n                    Artificial microRNA (amiRNA)-mediated inhibition of viral replication has recently gained importance as a strategy for antiviral therapy. In this study, we evaluated the benefit of using the amiRNA vector against Japanese encephalitis virus (JEV). We designed three single amiRNA sequences against the consensus sequence of 3\u2032 untranslated region (3\u2032UTR) of JEV and tested their efficacy against cell culture-grown JEV Vellore strain (P20778) in neuronal cells. The binding ability of three amiRNAs on 3\u2032UTR region was tested\n                    <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                    in HEK293T cells using a JEV 3\u2032UTR tagged with luciferase reporter vector. Transient transfection of amiRNAs was nontoxic to cells as evident from the MTT assay and caused minimal induction in interferon-stimulated gene expression. Furthermore, our result suggested that transient expression of two amiRNAs (amiRNA #1 and amiRNA #2) significantly reduced intracellular viral RNA and nonstructural 1 (NS1) protein, as well as diminished infectious viral particle release up to 95% in the culture supernatant as evident from viral plaque reduction assay. Overall, our results indicated that RNA interference based on amiRNAs targeting viral conserved regions at 3\u2032UTR was a useful approach for improvements of nucleic acid inhibitors against JEV.\n                  <\/jats:p>","DOI":"10.1089\/nat.2018.0743","type":"journal-article","created":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T14:45:12Z","timestamp":1542725112000},"page":"357-365","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":17,"title":["Artificial MicroRNA-Mediated Inhibition of Japanese Encephalitis Virus Replication in Neuronal Cells"],"prefix":"10.1177","volume":"28","author":[{"given":"Himani","family":"Sharma","sequence":"first","affiliation":[{"name":"Vaccine and Infectious Disease Research Center (VIDRC), Translational Health Science and Technology Institute (THSTI), Faridabad, India."},{"name":"Regional Center for Biotechnology, NCR Biotech Science Cluster, Faridabad, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aarti","family":"Tripathi","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Research Center (VIDRC), Translational Health Science and Technology Institute (THSTI), Faridabad, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bharti","family":"Kumari","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Research Center (VIDRC), Translational Health Science and Technology Institute (THSTI), Faridabad, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudhanshu","family":"Vrati","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Research Center (VIDRC), Translational Health Science and Technology Institute (THSTI), Faridabad, India."},{"name":"Regional Center for Biotechnology, NCR Biotech Science Cluster, Faridabad, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arup","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Research Center (VIDRC), Translational Health Science and Technology Institute (THSTI), Faridabad, India."},{"name":"Regional Center for Biotechnology, NCR Biotech Science Cluster, Faridabad, India."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,11,30]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6750-12-42"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.21.11531-11535.2003"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkh278"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2008.231"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2013.08.010"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2009.07.012"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2016.08.019"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2012.0405"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2017.09.018"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13312-015-0728-5"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq074"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030096"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2007.11.014"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr487"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.3390\/v9060137"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-80-7-1665"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkl143"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2016.25"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S154458"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2017.04.010"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.17.8505-8517.2002"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2013.09.024"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1001258"}],"container-title":["Nucleic Acid Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/nat.2018.0743","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/nat.2018.0743","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/nat.2018.0743","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T21:00:57Z","timestamp":1777669257000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/nat.2018.0743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,30]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12,1]]}},"alternative-id":["10.1089\/nat.2018.0743"],"URL":"https:\/\/doi.org\/10.1089\/nat.2018.0743","relation":{},"ISSN":["2159-3337","2159-3345"],"issn-type":[{"value":"2159-3337","type":"print"},{"value":"2159-3345","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,30]]}}}